What is the recommended high‑dose vitamin D3 (cholecalciferol) schedule, including loading and maintenance dosing and monitoring, for an adult patient without hypercalcemia, granulomatous disease, severe renal impairment, or active sarcoidosis?

High-Dose Vitamin D3 Schedule

For adults with vitamin D deficiency (25(OH)D <30 ng/mL), treat with 50,000 IU of vitamin D3 once weekly for 8 weeks, followed by maintenance therapy of 1,500-2,000 IU daily. 1

Loading Phase (Correction of Deficiency)

The most widely endorsed high-dose regimen is:

• 50,000 IU vitamin D3 (cholecalciferol) once weekly for 8 weeks 1
• Alternative: 6,000 IU daily for 8 weeks (equivalent cumulative dose) 1

This loading approach achieves 25(OH)D levels >30 ng/mL in most patients. The Endocrine Society guideline specifically recommends this as the standard correction protocol for vitamin D deficiency 1.

Important caveat: Avoid single annual bolus doses ≥500,000 IU, as these have been associated with increased fall and fracture risk 2, 3. Daily, weekly, or monthly dosing strategies are preferred over very large, infrequent doses.

Maintenance Phase

After completing the 8-week loading phase:

• 1,500-2,000 IU vitamin D3 daily 1
• Alternative intermittent dosing: 50,000 IU monthly or 100,000 IU every 3 months (for standard-risk patients) 2

The rule of thumb: each 1,000 IU daily increases 25(OH)D by approximately 10 ng/mL, though individual responses vary 2.

Special Populations Requiring Higher Doses

Obesity, malabsorption syndromes, or medications affecting vitamin D metabolism (anticonvulsants, glucocorticoids):

• Loading: 6,000-10,000 IU daily for 8-12 weeks 1
• Maintenance: 3,000-6,000 IU daily 1

These patients require 2-3 times higher doses due to sequestration in adipose tissue or enhanced catabolism 1.

Monitoring Schedule

• Baseline 25(OH)D measurement before initiating high-dose therapy (except in specific low-risk groups like institutionalized elderly) 2
• Recheck 25(OH)D after ≥3 months of supplementation to confirm adequate response 2
• For intermittent dosing, measure just prior to the next scheduled dose 2
• Adjust dosing if levels remain <30 ng/mL despite adherence 2

Calcium monitoring is only necessary in patients with conditions predisposing to hypercalcemia (primary hyperparathyroidism, granulomatous disease) 2, 1.

Safety Considerations

Target range: 30-50 ng/mL is optimal for most health outcomes 2. Levels of 30-44 ng/mL provide maximal benefit without additional advantage from higher concentrations 2.

Safety threshold: 100 ng/mL should be considered the upper safety limit, though toxicity typically requires daily intake >100,000 IU or sustained levels >100 ng/mL 2. Doses up to 10,000 IU daily for several months have not caused adverse events in healthy adults 2.

Absolute contraindications to high-dose therapy:

• Active granulomatous disease (sarcoidosis, tuberculosis, chronic fungal infections) - these patients have unregulated extrarenal 1α-hydroxylase activity in macrophages, converting 25(OH)D to active 1,25(OH)₂D, causing severe hypercalcemia even with modest supplementation 1, 4
• Pre-existing hypercalcemia
• Hypervitaminosis D

Formulation Preference

Vitamin D3 (cholecalciferol) is strongly preferred over vitamin D2 (ergocalciferol) for intermittent dosing regimens, as D3 maintains serum levels longer 2, 5. For daily dosing, both forms have similar efficacy, though D3 avoids assay specificity issues 2.

Common Pitfalls to Avoid

1. Don't use very large annual doses: The 500,000 IU annual dose increased falls and fractures 2, 3
2. Don't use calcitriol or 1α-hydroxylated forms to treat nutritional vitamin D deficiency 6
3. Don't supplement patients with active granulomatous disease without extreme caution and close calcium monitoring 1, 4
4. Don't assume compliance: Intermittent dosing (weekly/monthly) may improve adherence compared to daily regimens 2

Practical Dosing Algorithm

Step 1: Measure baseline 25(OH)D

• If <30 ng/mL → proceed to loading phase
• If 20-30 ng/mL → can use lower loading dose (e.g., 25,000 IU weekly × 8 weeks) 7

Step 2: Loading phase

• Standard: 50,000 IU weekly × 8 weeks 1
• Obesity/malabsorption: 6,000-10,000 IU daily × 8-12 weeks 1

Step 3: Maintenance

• Standard: 1,500-2,000 IU daily 1
• Obesity/malabsorption: 3,000-6,000 IU daily 1

Step 4: Recheck 25(OH)D at 3 months

• If <30 ng/mL: increase maintenance dose
• If 30-50 ng/mL: continue current dose
• If >70 ng/mL: reduce dose slightly (though still safe) 2